openPR Logo
Press release

Antisense Oligonucleotides Market Opportunity Analysis, 2026

08-07-2018 03:23 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Antisense Oligonucleotides Market Opportunity Analysis, 2026

Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen to treat cytomegalovirus retinitis, mipomersen to treat high cholesterol, etc.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1879

Antisense Oligonucleotides Market Drivers:-

One of the major factors driving growth of the global antisense oligonucleotides market is increasing number of launches pertaining to novel Antisense Oligonucleotides products by key players in the market. For instance, in 2015, Exiqon A/S acquired by Qiagen launched new LNA Antisense Oligonucleotide GapmeRs. LNA Antisense Oligonucleotide GapmeRs is used for inactivation of RNA in functional analysis. Antisense LNA is an alternative to existing siRNAs. LNA Antisense Oligonucleotide are designed using advanced bioinformatics algorithm, which is combined with LNA (locked nucleic acid).

Furthermore, mergers and acquisitions by key players, in order to enhance their product offerings is expected to be a major driver for global antisense oligonucleotides market growth. For instance, in February 2018, Takeda Pharmaceuticals Company Ltd.—a pharmaceutical company—merged with Wave Life Sciences Ltd., which is involved in nuclei acid therapeutics. Takeda Pharmaceuticals has merged with Wave Life Sciences Ltd. to develop antisense oligonucleotides for central nervous system disorder, which includes Lou Gehrig’s disease, Frontotemporal dementia (FTD), Spinocerebellar ataxia type 3 (SCA3), and huntington’s disease. Lou Gehrig’s disease is also called as Amyotrophic lateral sclerosis (ALS). This acquisition will also help Takeda in gaining market share.

Robust pipeline is also another factor aiding in growth of the global market. For instance, in 2016 Ionis Pharmaceuticals completed phase 2 clinical trials of its ISIS CRP Rx. ISIS 329993 is an antisense oligonucleotide, which targets CRP (C reactive protein) in patients with paroxysmal atrial fibrillation. In 2015, Achieve Life Sciences completed Phase 2 clinical trials of its OGX 427. OGX 427 is used to treat castration resistant prostate cancer.

Antisense Oligonucleotides Market Regional Analysis:-

North America is expected to be the dominant region in the global antisense oligonucleotides market over the forecast period. This is owing to increasing approvals of new antisense oligonucleotide drugs in the region. For instance, in 2018, U.S. FDA approved Nusinersen, which is marketed as Spinraza from Biogen Inc.—a multinational biotechnology company. Nusinersen is the first drug approved for the treatment of Spinal muscular Atrophy (SMA). Moreover, robust pipeline is expected to contribute significantly to North America antisense oligonucleotides market growth. For instance, in 2017, Bio Path Holding’s—an oncology focused biotechnology company— drug BP 1001 (liposomal Grb2 antisense oligonucleotide) was in phase 2 clinical trials. BP 1001 (liposomal Grb2 antisense oligonucleotide) is used to treat chronic myelogenous leukemia.

Key players in Europe are focusing on strategic mergers and acquisitions in order to enhance their product offerings in antisense oligonucleotides. This is further expected to aid in growth of the Europe antisense oligonucleotides market size. For instance, in 2014, Astra Zeneca Plc.,—a multinational pharmaceutical and biopharmaceutical company—merged with Ionis Pharmaceuticals, a pharmaceutical company. Astra Zeneca Plc. has strategically merged with Ionis Pharmaceuticals to develop delivery methods for antisense oligonucleotides, which would help in targeting the desired tissue more effectively. The other objective of this merger was to develop Ligand Conjugation Antisense (LICA) Technology. Furthermore, robust pipeline of key players is also expected to aid in growth of the market to a certain extent. For instance, in 2016, Ionis Pharmaceuticals, a pharmaceutical company completed phase 2 clinical trial of its drug IONIS STAT 3Rx. IONIS STAT 3Rx is used in treatment of advanced cancers and lymphoma.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1879

Antisense Oligonucleotides Market Key Players:-

Key players in global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., and Rxi Pharmaceuticals Inc.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotides Market Opportunity Analysis, 2026 here

News-ID: 1167031 • Views: 633

More Releases from Coherent Market Insights

Sustained Release Coating Market See Incredible Growth 2023-2030 | Evonik, BASF …
The global "Sustained Release Coating Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Sustained Release Coating market report highlight the latest development trends across different regions. This report provides key market players with business insights and growth opportunities. The Sustained Release Coating market research is an intelligence report that contains
Almond Drinks Market Set To Worldwide Growth, New Applications and Revenues by 2 …
Coherent Market Insights Published the Latest Almond Drinks Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast period 2022-2030. The Almond Drinks business report's clear, reliable, and thorough market data and information will undoubtedly aid in business development and boost return on investment (ROI). The region that is predicted to generate the greatest potential in the global Almond Drinks market is
Partial Knee Arthroplasty Market Analysis, Growth by Top Companies, Trends by Ty …
The global "Partial Knee Arthroplasty Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Partial Knee Arthroplasty market report highlight the latest development trends across different regions. This report provides key market players with business insights and growth opportunities. The Partial Knee Arthroplasty market research is an intelligence report that contains
Residential Water Treatment Devices Market Analysis by Growth, Development Regio …
Coherent Market Insights Published the Latest Residential Water Treatment Devices Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast period 2022-2030. The Residential Water Treatment Devices business report's clear, reliable, and thorough market data and information will undoubtedly aid in business development and boost return on investment (ROI). The region that is predicted to generate the greatest potential in the global

All 5 Releases


More Releases for Antisense

Antisense and RNAi Therapeutics Market Report Up to 2031
Antisense and RNAi Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues Where is the Antisense and RNAi Therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there. Download Exclusive Sample of Report @ https://www.visiongain.com/report/antisense-and-rnai-therapeutics-market/#download_sampe_div Discover how to stay ahead Our Antisense and RNAi Therapeutics report
Global Antisense and RNAi Therapeutics Market Analysis (2020-2025)
Global Info Research offers a latest published report on Antisense and RNAi Therapeutics Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Antisense and RNAi Therapeutics Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. Click to view the full report
Antisense Therapy Market: Competitive Dynamics & Global Outlook 2020-2025
This report also researches and evaluates the impact of Covid-19 outbreak on the Antisense Therapyindustry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Antisense Therapyand market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). Global Antisense Therapy Market Overview: GLOBAL INFO RESEARCHhas evaluated the global Antisense Therapy marketin its latestresearch report. The research report, titled [Global Antisense Therapy
Antisense Therapy Market to Witness Robust Expansion by 2025
LP INFORMATION recently released a research report on the Antisense Therapy market analysis, which studies the Antisense Therapy's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Antisense Therapy Market 2020-2025" Research Report categorizes the global Antisense Therapy market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
Antisense Oligonucleotides Market Report 2017 – 2027: By Application
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning
PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Anal …
Summary GlobalDatas "PharmaSphere: Emerging Biotechnologies - Antisense RNAi Therapeutics Market Analysis" report is an essential source of information and analysis on the RNA interference (RNAi) therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends, GlobalData provides an in-depth analysis of the current and future growth drivers of the RNAi therapy market. The report discusses the key factors shaping and driving the RNAi therapy business, and provides insights